SCHOFIELD, Wis., May 11, 2009 (GLOBE NEWSWIRE) -- PuraMed Bioscience, Inc. (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches announced today that they will be launching a series of 8 articles over as many weeks in the Wall Street Journal (WSJ) and the Investors Business Daily (IBD) newspaper publications.
